CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
stocks
ASX top pick remains cheap with narrowing brand focus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,804.60 | 39.10 | 0.45% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,110.29 | 297.67 | -1.22% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 63,239.52 | 939.75 | -1.46% |
| NZX 50 Index | 13,181.08 | 72.57 | -0.55% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,608.60 | 45.10 | 0.53% |
| SSE Composite Index | 3,974.90 | 18.33 | -0.46% |